Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

Core Insights - Fresenius Medical Care AG (FME) will present new research on hemodiafiltration (HDF) and artificial intelligence (AI) at the ASN Kidney Week 2025, highlighting improved outcomes for kidney patients [1][2] Research and Innovation - The research emphasizes FME's commitment to patient-centered innovation, showcasing how advanced therapies like HDF can enhance real-world outcomes [2] - FME's Global Medical Office will present multiple abstracts on critical nephrology topics, reinforcing the company's dedication to advancing kidney care through innovation and evidence-based science [2][4] Key Presentations and Events - Notable presentations include the association between HDF and reduced risk of cardiovascular and fluid-related hospitalizations, with one study accepted for oral presentation [4][5] - FME will host a breakfast symposium titled "HighVolumeHDF: The Next Standard of Care for U.S. Patients – Evidence and Practical Use" during ASN [5] - The Renal Research Institute (RRI) will conduct its annual symposium focusing on AI and digital tools in kidney care [5] AI Applications - Research will showcase an AI model predicting fall risk in dialysis patients and a clinician-facing AI chatbot designed to support HDF implementation [5] - The potential of generative AI in planning safe and clinically appropriate diets for hemodialysis patients will also be evaluated [5] Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally, with around 300,000 patients receiving dialysis treatments through its network of 3,676 clinics [7]